Atrial and ventricular arrhythmias with immune checkpoint inhibitor therapy in patients without evidence of myocarditis

Back

ESC Professional Premium Access

Atrial and ventricular arrhythmias with immune checkpoint inhibitor therapy in patients without evidence of myocarditis

Session: T-cells, checkpoint inhibitors, and cardiac complications

Topic: Cardio-Oncology

Speaker: Doctor J. Heemelaar (Boston, US)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Julius Heemelaar

Massachusetts General Hospital, Boston (United States of America)

0 follower

7 more presentations in this session

Cardiovascular complications of chimeric antigen receptor (CAR)-T cell therapy

Speaker: Associate Professor F. Guerra (Ancona, IT)

Arterial inflammation induced by immune checkpoint inhibitors assessed on 18F-FDG PET-CT scans in stage III/IV melanoma patients

Speaker: Miss E. Polomski (Leiden, NL)

Immune checkpoint inhibitors and atherosclerotic cardiovascular events: a retrospective cohort study

Speaker: Doctor S. Tan (Melbourne, AU)

Gender differences in cardio-oncology care of patients treated with immune checkpoint inhibitor therapy

Speaker: Associate Professor R. Mincu (Essen, DE)

Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels and reduces myocardial strain through NLRP3 and MyD-88 pathways

Speaker: Doctor N. Maurea (Naples, IT)

Access the full session

T-cells, checkpoint inhibitors, and cardiac complications

Speakers: Doctor J. Heemelaar, Associate Professor F. Guerra, Miss E. Polomski, Doctor S. Tan, Associate Professor R. Mincu...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Atrial and ventricular arrhythmias with immune checkpoint inhibitor therapy in patients without evidence of myocarditis

About the speaker

Doctor Julius Heemelaar

7 more presentations in this session

Cardiovascular complications of chimeric antigen receptor (CAR)-T cell therapy

Arterial inflammation induced by immune checkpoint inhibitors assessed on 18F-FDG PET-CT scans in stage III/IV melanoma patients

Immune checkpoint inhibitors and atherosclerotic cardiovascular events: a retrospective cohort study

Gender differences in cardio-oncology care of patients treated with immune checkpoint inhibitor therapy

Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels and reduces myocardial strain through NLRP3 and MyD-88 pathways

Access the full session

T-cells, checkpoint inhibitors, and cardiac complications

About the event

ESC Congress 2023

ESC 365 is supported by